With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.192130-34-0,tert-Butyl 4-(2-aminoethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.
A stock solution of lithium l-benzyl-2-(l,5-dimethyl-6-oxo-l,6-dihydropyridin-3-yl)-lH- imidazole-4-carboxylate (for an example preparation, see Intermediate 13, 198 mg, 0.60 mmol) and HATU (228 mg, 0.60 mmol) was prepared in DMF (3 ml_), to which was added DIPEA (0.33 ml_, 1.9 mmol). The solution was shaken and 0.5 ml. was transferred to a vial containing tert-butyl 4-(2-aminoethyl)piperazine-l-carboxylate (0.12 mmol). The vial was capped and stood at RT for 2 h. The solvent was removed and the sample redissolved in DMSO (0.5 ml.) and purified by MDAP (Method B). The solvent was removed under a stream of nitrogen and the sample dissolved in a solution of DCM (0.5 ml.) and 4M HCI in 1,4-dioxane (0.5 ml_). The solution was capped and stood at RT for 1 h, after which the solvent was removed to afford the title compound as the hydrochloride salt (34.1 mg, 0.07 mmol, 72percent). LCMS (System A): tRET = 0.44 min; MH+ 435., 192130-34-0
The synthetic route of 192130-34-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED; BAXTER, Andrew; BIT, Rino, Antonio; BROWN, John, Alexander; HIRST, David; HUMPHREYS, Philip; JONES, Katherine, Louise; PATEL, Vipulkumar, Kantibhai; (124 pag.)WO2018/41964; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics